ARCHIVES

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Study Section Members Seek NIH Use Of Normalization, Sliding Scale

April 16, 1982

President’s FY 1992 Budget Seeks $1.81 Billion For NCI, 5.6% Increase, But $800M Below Byspass

February 8, 1991

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

May 8, 1987

Bladder Cancer Survival Rate Rises With Neoadjuvant Chemo

September 26, 2003

Swiss Report On Radiotherapy Mortality Questioned

January 7, 1977

NIH Grantees Win Nobel Prizes In Medicine, Chemistry

October 9, 2009